hydron;(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol;bromide

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: hydron;(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol;bromide
• 化学式: C17H24BrNO
• 分子量: 338.3
• InChiKey: WVFGKGPFQSEWON-DYWKTHLTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  23.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Process for the Production of Levorphanol and Related Compounds
  申请人：Haar Joseph P.

  公开号：US20080146805A1

  公开（公告）日：2008-06-19

  A process for the production of morphinans with higher purity and yield, when compared to the conventional process, is described. Specifically, the process may be used to prepare levorphanol, levorphanol tartrate, and levorphanol tartrate dihydrate in high yields and substantially free from several process impurities.

  本发明描述了一种生产吗啡类化合物的工艺，与传统工艺相比，可获得更高纯度和产量。具体而言，该工艺可用于制备左旋麻黄碱、左旋麻黄碱酒石酸盐和左旋麻黄碱酒石酸盐二水合物，其收率高，基本上不含多种工艺杂质。
• Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
  申请人：Babul Najib

  公开号：US20120065221A1

  公开（公告）日：2012-03-15

  The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.

  本发明涉及口服、治疗有效的3-羟基-N-甲基吗啡酮的延迟作用、延长释放药物组成物，包括延迟起效、延长释放剂型及其使用。
• PROCESS FOR THE PRODUCTION OF LEVORPHANOL AND RELATED COMPOUNDS
  申请人：MALLINCKRODT, INC.

  公开号：EP1781616A2

  公开（公告）日：2007-05-09
• EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE
  申请人：Relmada Therapeutics, Inc.

  公开号：EP2448406B1

  公开（公告）日：2016-04-20
• [EN] PROCESS FOR THE PRODUCTION OF LEVORPHANOL AND RELATED COMPOUNDS<br/>[FR] FABRICATION DE LEVORPHANOL ET DE COMPOSES APPARENTES
  申请人：MALLINCKRODT INC

  公开号：WO2006023669A2

  公开（公告）日：2006-03-02

  A process for the production of morphinans with higher purity and yield, when compared to the conventional process, is described. Specifically, the process may be used to prepare levorphanol, levorphanol tartrate, and levorphanol tartrate dihydrate in high yields and substantially free from several process impurities.